Small Cell Lung Cancer Market
May 21, 2024
Amgen’s IMDELLTRA FDA Approval; J&J’s Proteologix Acquisition; Bristol Myers Squibb’s BREYANZI FDA Approval; AbbVie and Gilgamesh Pharmaceuticals’ Agreement; Eisai’s LEQEMBI FDA Fast Track Status
IMDELLTRA Receives FDA Approval as the First T-Cell Engager Therapy for Advanced Small Cell Lung Cancer Amgen has reported that the FDA has approved IMDELLTRA™ (tarlatamab-dlle) for treating adult patients with extensive-stage small cell lung cancer (ES-SCLC) who have experienced disease progression following pl...
Read More...
Mar 14, 2022
Small Cell Lung Cancer Treatment Market Propels Due to Extremely Robust Pipeline
Small Cell Lung Cancer (SCLC) is a particularly aggressive type of lung cancer. It is distinguished by the rapid and uncontrolled growth of certain cells in the lungs. A tumor forms eventually, and cancer can spread to other parts of the body. Small Cell Lung Cancer treatment usually involves chemotherapy, radiothe...
Read More...
Jul 03, 2020
Small Cell Lung Cancer Market Booms with an Influx of Companies and Robust Pipeline
As per DelveInsight, the Small cell lung cancer market size is expected to increase at a CAGR of 15.2% during the study period (2017–30) attributing to a rich pipeline, healthcare spending, improved R&D, and discovery of novel targets. Small cell lung cancer (SCLC) or Small cell lung carcinoma is an aggressi...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
